Peroxitech Therapeutics is a technology company.
Peroxitech Therapeutics has raised $25.0M across 1 funding round.
Peroxitech Therapeutics has raised $25.0M in total across 1 funding round.
Peroxitech Therapeutics has raised $25.0M in total across 1 funding round.
Peroxitech Therapeutics's investors include Perceptive Advisors.
Peroxitech Therapeutics is a privately held biopharmaceutical company developing PIP-2, a novel peptide therapeutic targeting a newly discovered signaling pathway to treat acute lung injury (ALI), a life-threatening condition with no approved treatments.[1][2][4] PIP-2 aims to protect, rescue, and improve survival in ALI by addressing oxidative injury and cytokine storm cascades, serving critically ill patients in ICUs affected by conditions like sepsis, pneumonia, or trauma.[2][5] The company has shown strong early momentum, securing a $25 million Series A investment in June 2022 from Perceptive Xontogeny Venture (PXV) Fund to advance preclinical development into clinical trials, following compelling preclinical data with 70% survival rates in animal models versus 0% in controls.[2][3]
Peroxitech emerged as a biotech startup from the University of Pennsylvania, leveraging breakthrough science from the Penn Center for Innovation Ventures to commercialize PIP-2, a new chemical entity (NCE) discovered via a novel oxidative injury pathway.[2][6] The idea stemmed from identifying this pathway related to ALI's cytokine storm cascade, with early proof-of-concept established through strategic preclinical studies in multiple ALI models to de-risk development.[2] Pivotal moments include standout animal mortality studies demonstrating 70% survival with PIP-2, attracting the $25M Series A in 2022 led by PXV, and recognition as a Top BioTech Startup in 2023; Thomas Han serves as CEO.[2][3]
Peroxitech rides the wave of precision biopharma for unmet respiratory needs, amplified by post-COVID awareness of ALI/ARDS prevalence (affecting ~200,000 US patients yearly with 40% mortality).[2] Timing is ideal amid rising demand for cytokine-targeted therapies, as ALI's lack of FDA-approved drugs creates a massive market opportunity estimated in billions, fueled by aging populations and infectious disease threats.[2] Market forces like accelerated venture funding for de-risked assets (e.g., strong preclinical survival data) favor Peroxitech, positioning it to influence ICU standards and inspire pathway-focused spinouts from academia.[2][3]
Peroxitech is primed to initiate clinical trials for PIP-2 post-Series A, potentially yielding first human data in 2026-2027, with success hinging on replicating preclinical efficacy in ALI patients.[2][3] Trends like AI-driven drug discovery and combo therapies for cytokine storms will shape its path, while expanded funding or Big Pharma partnerships could accelerate commercialization. Its influence may grow by validating novel ALI pathways, filling a critical gap and boosting investor confidence in university-derived biotechs—echoing its origins as a beacon for oxidative injury breakthroughs.[1][2]
Peroxitech Therapeutics has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in December 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2022 | $25.0M Series A | Perceptive Advisors |